GSK•benzinga•
GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion
Summary
GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga